Martin Deterre is a graduate of Polytechnique and MIT with a PhD and 13 years of experience in MedTech innovation. Currently, he is the CEO of Theraclion, a publicly traded startup developing and commercializing breakthrough robotic therapeutic ultrasound (HIFU) devices aimed at revolutionizing surgery with non-invasive robotic procedures. Theraclion's products are on the market for varicose veins, thyroid nodules, and breast fibroadenoma treatments, generating multi-million euros in annual revenues with strong ambitions in the US, Chinese, and EU markets. Deterre successfully led an R&D team to bring an artificial vision, retinal implant device from academic research to FDA and EU clinical trial approval in four years, enabling blind patients to read words again and advancing the project to pivotal clinical study. He is known for his execution and delivery orientation, field/customer/patient-driven approach, creative thinking, and leadership in fast-paced startup environments.

Experience

• PRIMA Project Leader (2013 - 2020)

  Pixium Vision

Education

• PhD, Micro & Nano Systems (2010 - 2013)

  IEF, Univ. Paris-Sud, Orsay, France

• MS, Mechanical Engineering (2008 - 2010)

  Massachusetts Institute of Technology (MIT)